PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
30 hedge funds and large institutions have $4.19M invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 4 closing their positions.
282% more capital invested
Capital invested by funds: $1.1M → $4.19M (+$3.09M)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
7% more funds holding
Funds holding: 28 → 30 (+2)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.87M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$17K |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$12.3K |
| 4 |
FCI
Financial Counselors Inc
Overland Park,
Kansas
|
+$12.2K |
| 5 |
CIC
Carnegie Investment Counsel
Pepper Pike,
Ohio
|
+$9.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$72.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19K |
| 3 |
ACM
Academy Capital Management
Waco,
Texas
|
-$17K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$16.2K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$12.5K |
PVCT Hedge Fund Activity: Q3 2014 in Review
30 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2014, worth a combined $4.19M — up 282% from $1.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PVCT positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $2.87M. The largest seller was Virtu KCG Holdings, cutting an estimated $72.2K.
- 30 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2014, up from 28 in Q2 2014.
- Funds reported $4.19M of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2014, up 282% quarter-over-quarter.
- 6 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2014 and 4 closed out, a net change of +2 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q3 2014 was Vanguard Group, an estimated $2.87M added.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q3 2014 was Virtu KCG Holdings, an estimated $72.2K sold.
Based on aggregated 13F filings for Q3 2014.